Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-1826
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Parenteral
01
Overview
miR-1826 is a tumor-suppressive microRNA that has been investigated for its potential therapeutic role in bladder cancer. It functions by targeting the 3' untranslated regions (3'UTR) of several oncogenic mRNAs, specifically those encoding beta-catenin (CTNNB1), MEK1 (MAP2K1), and vascular endothelial growth factor C (VEGFC). By down-regulating these targets, miR-1826 inhibits the Wnt/beta-catenin and Ras-Raf-MEK-ERK signaling pathways, which are critical for tumor progression. Preclinical studies have demonstrated that miR-1826 expression is significantly reduced in bladder cancer tissues and that its restoration leads to decreased cell viability, invasion, and migration, alongside increased apoptosis and G1 cell cycle arrest.
- Other names
- hsa-miR-1826hsa-miR1826hsa-miR 1826
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)CTNNB1 (Beta-catenin)VEGFC (VEGF-C)
Beyond the preview
Go deeper on miR-1826.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-1826.